Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8491 to 8505 of 8916 results

  1. COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES23)

    This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.

    Withdrawn advice

  2. COVID-19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 (ES27)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn advice

  3. COVID-19 rapid evidence summary: vitamin D for COVID-19 (ES28)

    This evidence summary has been updated and replaced by the COVID-19 rapid guideline on vitamin D (NG187).

    Withdrawn advice

  4. COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn advice

  5. COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn advice

  6. FebriDx for C-reactive protein and Myxovirus resistance protein A testing in primary care (MIB114)

    This advice has been updated and replaced by NICE medtech innovation briefing 224.

    Withdrawn advice

  7. Daylight for treating generalised anxiety disorder in adults (MIB309)

    August 2023: This medtech innovation briefing (MIB) has been withdrawn at the company’s request as the evidence for the technology has moved on and the company expect to seek a NICE guidance output in due course.

    Withdrawn advice

  8. Ventripoint Medical System Plus for measuring heart volume and function (MIB310)

    February 2023: The medtech innovation briefing on Ventripoint Medical System Plus for measuring heart volume and function has been withdrawn as the company have withdrawn from the process.

    Withdrawn advice

  9. QbTest for the assessment of attention deficit hyperactivity disorder (ADHD) (MIB318)

    This advice has been updated and replaced by NICE healthtech guidance 729.

    Withdrawn advice

  10. BPMpathway for rehabilitation support in joint replacement surgery (MIB319)

    MIB319 BPMpathway for rehabilitation support in joint replacement surgery has been withdrawn. This is because factual inaccuracies have been identified. NHS England no longer fund NICE to produce or maintain medtech innovation briefings, therefore these are no longer being reviewed.

    Withdrawn advice

  11. Flow transcranial direct current stimulation for treating depression (MIB324)

    May 2024: This medtech innovation briefing has been withdrawn. This is because the evidence for the technology has changed since it was published. NHS England no longer funds NICE to produce or maintain medtech innovation briefings, so these are no longer being reviewed.

    Withdrawn advice

  12. Episcissors-60 for guided mediolateral episiotomy (MIB33)

    This advice has been updated and replaced by NICE medical technologies guidance 47.

    Withdrawn advice

  13. AliveCor Heart Monitor and AliveECG app (Kardia Mobile) for detecting atrial fibrillation (MIB35)

    This advice has been updated and replaced by NICE medtech innovation briefing 232.

    Withdrawn advice

  14. The BCM – Body Composition Monitor for managing fluid in people having dialysis (MIB41)

    This advice has been updated and replaced by NICE guidance HTG441 

    Withdrawn advice

  15. EndoPredict gene expression profiling assay for assessing risk of breast cancer recurrence (MIB44)

    This advice has been updated and replaced by NICE diagnostics guidance 34.

    Withdrawn advice